Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,930,000 shares, a decrease of 5.5% from the March 31st total of 3,100,000 shares. Currently, 10.4% of the company’s stock are sold short. Based on an […]
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.20 and traded as high as $3.16. Brainstorm Cell Therapeutics shares last traded at $2.78, with a volume of 440,422 shares trading […]
Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,100,000 shares, a growth of 29.7% from the March 15th total of 2,390,000 shares. Currently, 11.0% of the company’s stock are sold short. Based on an […]